<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

NSCLC PDX Models with EGFR Exon 20 Insertions Developed

Activating EGFR mutations are oncogenic drivers in a significant proportion of NSCLC cases. Patients with classical EGFR mutations usually respond well to tyrosine kinase inhibitors (TKI). However, the efficacy of EGFR TKIs on NSCLC cases harboring non-canonical mutations (e.g. exon 20 insertions) is less clear.